CORE 2 (Recruiting)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of
Olezarsen (ISIS 678354) Administered Subcutaneously to Patients with Severe Hypertriglyceridemia
- Medicine
- Olezarsen (ISIS 678354)
- Population
- ASCVD
- Phase
- III
- Starting year
- 2022